{"id":12717,"date":"2024-10-11T16:57:28","date_gmt":"2024-10-11T14:57:28","guid":{"rendered":"https:\/\/valintermed.com\/?p=12717"},"modified":"2024-10-11T16:57:28","modified_gmt":"2024-10-11T14:57:28","slug":"filadelfiya-otritsatelnyy-hronicheskiy-mieloidnyy-leykoz","status":"publish","type":"post","link":"https:\/\/valintermed.com\/en\/medlibrary\/chronic-myeloid-leukemia\/","title":{"rendered":"Philadelphia-negative chronic myeloid leukemia"},"content":{"rendered":"
<\/div>\n

Chronic myeloid leukemia (CML) is a hematological malignancy characterized by an increase in the number of myeloid cells in the bone marrow and peripheral blood. The main mutation associated with this disease is chemo-separation of the BCR and ABL genes, resulting in the formation of a chimeric BCR-ABL gene. This gene encodes a tyrosine kinase that promotes uncontrolled proliferation of myeloid cells. Patients with CML have specific clinical manifestations, including increasing weakness, sweating, fever, and an enlarged spleen. Philadelphia-positive (Ph+) CML is associated with the presence of this mutation and demonstrates an aggressive course with the possibility of transition to a blast crisis.<\/p>\n

\n
\n

Content<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n